HHS Lets Licensed Pharmacies Compound Six Unapproved Peptides, Overruling FDA Scientists

Peptides are short chains of amino acids, the building blocks of proteins, and the human body produces many of them naturally. Over the past several years a subset of these molecules has become a fixture of the wellness internet, promoted by influencers, technology executives and figures in the Make America Healthy Again movement as tools for healing injuries, extending lifespan, sleeping better and improving complexion. The best known peptide products in mainstream medicine are the GLP-1 drugs such as Ozempic and Mounjaro, which are approved and regulated. The compounds at the center of the new federal action are not.

Compounding is a separate channel with a separate rulebook. Compounding pharmacies mix customized formulations, and in some cases produce specialty drugs in bulk, without going through the FDA approval process that a brand name or generic medicine must complete. The FDA retains some oversight of compounding facilities, but the 503A bulks list determines which bulk drug substances may lawfully be used in that channel at all.

The six peptides now in question are BPC-157 and TB-500, often taken together in a combination popularly known as the Wolverine stack, along with epitalon, promoted as a sleep and longevity aid, KPV, used for wound healing and inflammatory conditions, MOTS-c, used for obesity and osteoporosis, and Semax, a supplement for migraine and chronic pain. In 2023, safety concerns led the FDA to remove the six peptides from the list of drugs that compounding pharmacies could make, an action that removed 19 peptides from that list.

Kennedy has called himself a big fan of the treatments and has argued that the FDA should lift restrictions because Americans were importing unsafe products. That position collided with the judgment of the agency's own scientists, who say there is insufficient evidence to show whether the peptides are effective and that they are potentially dangerous. On October 28, 2026, the secretary moved the argument from persuasion to paperwork.

Key Facts

The policy is an interim enforcement discretion document, not an approval. Reuters reported on October 28 that Kennedy filed the measure with the Federal Register as his enforcement discretion policy, under which the department will not take enforcement action against licensed pharmacies, federal facilities or licensed physicians that compound BPC-157, TB-500, epitalon, KPV, MOTS-c and Semax while regulators consider whether to formally permit their use in compounded medicines. Ars Technica reported on October 28 that the rule is titled Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, that it was made available on the Federal Register that Wednesday, and that final publication was set for October 30. The document does not change the regulatory status of any peptide. It changes whether the government will sue over them.

Coverage extends to state licensed pharmacies, federal facilities and licensed physicians, and the policy requires patient specific prescriptions, traceable ingredients, quality testing, safety reporting and labeling. HHS framed the move as a black market crackdown, saying it does not grant FDA approval or establish clinical safety and effectiveness, and said legal compounding would discourage foreign research use only peptides.

AJMC reported on October 29 that the notice lists the Office of the Secretary as the issuing agency, is signed by Kennedy, and carries a docket and contact at the Office of the Assistant Secretary for Health rather than at the FDA, whereas the framework governing other nominated 503A ingredients was issued by the FDA as guidance for industry. AJMC also reported that FDA career scientists had recommended against adding any of the seven peptides reviewed at the July Pharmacy Compounding Advisory Committee meeting, including all six now covered.

The advisory committee itself is contested. The panel voted in July 2026 to recommend that the agency allow all six peptides in compounding, but before that vote Kennedy expanded the 12 member committee with eight new appointees, and at least six of the additions have ties to peptide related businesses or clinics. Ars Technica reported on October 28 that the arrangement raised conflict of interest concerns. HHS said previously that all members cleared standard ethics checks.

Analysts estimate the peptide industry could quickly become a $2 billion to $3 billion market if legitimized, and telehealth companies such as Hims & Hers Health have been preparing to roll out peptide offerings once cleared by federal regulators. AJMC reported on October 29 that four outside groups met with White House budget reviewers before release under Executive Order 12866: the American Academy of Peptide Medicine on October 21, Hims & Hers Health on October 23, and the Alliance for Pharmacy Compounding and the Center for Science in the Public Interest each on October 27, the day before the notice was filed. Lee Rosebush, chair of the American Academy of Peptide Medicine, called the policy a landmark regulatory milestone.

Analysis

What this really means is that the United States has stopped treating the peptide question as a scientific one and started treating it as a question of prosecutorial priorities. The evidence base did not change between the July advisory vote and the October filing. A rule issued by the Office of the Secretary, docketed outside the FDA, accomplishes by forbearance what would otherwise require undoing a 2023 listing decision. The agency keeps its scientists' conclusion and drops its enforcement posture.

The second judgment is about incentives. The policy's stated rationale, that legal compounding will displace gray and black market purchases, is a harm reduction argument. But creating a lawful domestic supply for six substances with little to no human data expands the population exposed to them. Scientific American reported on October 28 that the affected peptides are rarely taken alone and that there is very little research on what stacks of two or more peptides might do to health.

Robert Steinbrook, director of Public Citizen's Health Research Group, said Kennedy acted recklessly and unilaterally, warning of contamination, impurities and unknown side effects. Willie Underwood III, president of the American Medical Association, said the peptides have not undergone the rigorous testing required of FDA approved drugs and that compounding them without sufficient evidence puts patients at risk. The Partnership for Safe Medicines petitioned the FDA to disregard the advisory vote, arguing that the reconstituted committee violated the Federal Advisory Committee Act and the Ethics in Government Act, with executive director Shabbir Imber Safdar pointing to apparent conflicts of interest.

The bigger picture here is that enforcement discretion is becoming the default instrument of health policy, because it is fast, reversible and does not require a rulemaking record that would have to survive scrutiny of the committee that produced it. That is why it is fragile: a policy that exists only as a promise not to act can be withdrawn the same way it was issued, and the department has already said it may reconsider in whole or in part. Supporters who celebrated online, including sellers who wrote that peptides are back, are celebrating an administrative mood rather than a licensed indication.

Why It Matters

For patients, the practical change is access with a prescription and without a guarantee. Compounded drugs are not FDA approved, and the agency does not review their safety, effectiveness or quality before they are marketed. Someone who obtains BPC-157 after October 28 is getting a product made under quality and labeling requirements the policy describes, not one that has cleared a clinical trial.

For the federal system, the policy opens a seam between Washington and the states. Jeff Cohen, cofounder of the American Peptide Association, told Reuters the move could heighten federal state tension since states may not follow. A pharmacy in a state that reads its compounding rules strictly may still face consequences that HHS has just declined to impose, so the geography of access will depend on state capitals rather than the Federal Register.

For the wider drug supply, the precedent is the point. If a secretary can suspend enforcement for six bulk substances ahead of a formal listing decision, the same tool is available for the next set. The FDA removed these peptides from the compounding list in 2023 for safety reasons, and that finding has not been withdrawn. It has been placed in abeyance, and the difference will matter the first time a contaminated batch or an adverse event is reported.

Next Up

Written comments are due two weeks after the October 30 publication date, which puts the near term deadline in mid November 2026, and the docket will become the record that supporters and critics alike try to shape. As of July, the advisory committee was scheduled to review five more unapproved peptides in February, so the same argument is already queued for a second round.

The department kept an exit open, stating that HHS may revisit the policy in whole or in part if a safety signal or product quality issue arises. Whether that exit is used will depend less on the science, which has not moved, than on whether the market the policy legitimizes produces harm that cannot be handled with another memo.